ALXO ALX Oncology: Projected Price to Earnings

ALXO (ALX Oncology) - company brandmark

The valuation of ALX Oncology Holdings (ALXO) depends on the progress of clinical trials, as commercial revenue and pricing power are currently absent. The company's expected NTM P/E helps identify hidden market manipulations, while the 0.00 metric determines this level. The biopharma developer is creating less toxic CD47 blockers to combat tumors, competing for best-in-class status in a niche with a high risk of side effects.

alxoncology.com - ALXO Future Price to Earnings Multiple (period 07/04/2022 - 11/18/2026)

Metric breakdowns and analytics for ALX Oncology Holdings Inc. (ALXO)

Fundamental company analysis:alxoncology.com ALXO
Signature product of ALX Oncology

The forward P/E determines the stock price relative to projected earnings, measuring market expectations for business efficiency over future periods. By analyzing the forward P/E chart for ALX Oncology Holdings (ALXO), an investor can see how the diversification of ALX Oncology Holdings (ALXO) clinical programs targeting various tumors reduces regulatory risks, creating a fundamental margin of safety and justifying the issuer's current valuation.

Analysis of competing companies

Forward P/E Multiple IBRX|Immunocore Holdings plc (IMCR) - Forward Price to Earnings Multiple|Janux Therapeutics Inc - Projected Price to Earnings|Arcus Biosciences (RCUS) - Projected Price to Earnings Ratio|ZYME: Projected Price to Earnings|Future Price to Earnings Multiple TNGX (Tango Therapeutics, Inc.)|IOVA: Forward P/E Multiple|IMTX - Market Cap to Projected Earnings|Future Price to Earnings xencor.com|Projected Price to Earnings compasstherapeutics.com (CMPX)|Future Price to Earnings Replimune Group Inc (REPL)|Projected Price to Earnings Lyell Immunopharma Inc LYEL|Innate Pharma SA - Projected Price to Earnings|Forward P/E Multiple Pyxis Oncology, Inc. PYXS|CGEN - Future Price to Earnings|IOBT (iobiotech.com) - Price to Future Earnings Ratio|Sutro Biopharma, Inc (STRO) - Future Price to Earnings|Projected Price to Earnings Ratio MiNK (INKT)|Projected Price to Earnings HOWL|IMMX - Forward Price to Earnings Multiple|Forward P/E Multiple CUE|Market Cap to Future Earnings Ratio PDSB|Forward P/E Multiple SONN (Sonnet BioTherapeutics)|Future Price to Earnings Multiple MAIA|liminatuspharma.com - Forward P/E Multiple|Projected Price to Earnings Ratio LAVA Therapeutics|NextCure, Inc. (NXTC) - Future Price to Earnings|Leap Therapeutics Inc - Future Price to Earnings Multiple|INTS (Intensity Tx) - Forward P/E Multiple|Forward P/E Multiple senseibio.com|Future Price to Earnings Theriva Biologics (TOVX)|GRTS: Price to Expected Earnings Ratio|Forward P/E Multiple KA (kinetabio.com)|neximmune.com (NEXI) - Projected Price to Earnings Ratio|TSBX: Projected Price to Earnings|VCNX: Future Price to Earnings|HARP: Forward P/E Multiple